PMC:6909918 / 27456-29048 JSONTXT

{"target":"http://pubannotation.org/docs/sourcedb/PMC/sourceid/6909918","sourcedb":"PMC","sourceid":"6909918","source_url":"https://www.ncbi.nlm.nih.gov/pmc/6909918","text":"In 2018, the findings from a large, retrospective, multicenter, observational study compared the efficacy of regorafenib with fruquintinib (REGOTAS) in pretreated patients with mCRC, using subgroup propensity score analysis [20]. Although there were no differences in OS between regorafenib and TAS-102 (HR, 0.96; 95% CI, 0.78–1.18), adjusted analysis, using a propensity score, showed that regorafenib resulted in improved survival in patients aged \u003c65 years, and fruquintinib improved survival patients aged ≥65 years [20]. Also, the incidence of SAEs and FAEs were similar for regorafenib with fruquintinib [20]. The findings from this previous observational study were consistent with the findings from the present study, which also used an indirect comparison of fruquintinib and regorafenib and showed no significant difference in PFS or OS. However, the present study showed that the incidence of SAEs was reduced in patients treated with regorafenib when compared with fruquintinib, which might indicate that regorafenib may be safer in symptomatic patients with mCRC. The indirect comparison of AEs, SAEs, and FAEs for regorafenib, fruquintinib, and TAS-102 showed that the only significant difference was found for SAEs, and showed that the incidence of SAEs was more common in patients treated with fruquintinib compared with regorafenib, or TAS-102. This is an important finding for clinicians to be aware of who treat patients with mCRC. Otherwise, no differences were found from the indirect comparison in AEs at any grade or FAEs between fruquintinib, regorafenib, and TAS-102.","tracks":[{"project":"2_test","denotations":[{"id":"31790382-28894015-69134754","span":{"begin":225,"end":227},"obj":"28894015"},{"id":"31790382-28894015-69134755","span":{"begin":521,"end":523},"obj":"28894015"},{"id":"31790382-28894015-69134756","span":{"begin":611,"end":613},"obj":"28894015"}],"attributes":[{"subj":"31790382-28894015-69134754","pred":"source","obj":"2_test"},{"subj":"31790382-28894015-69134755","pred":"source","obj":"2_test"},{"subj":"31790382-28894015-69134756","pred":"source","obj":"2_test"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"2_test","color":"#c293ec","default":true}]}]}}